PE firm invests in growing eClinical solutions company

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Jirupong Manustrong)
(Image: Getty/ Jirupong Manustrong)

Related tags: Private equity, Private equity firm, eclinical, CTMS, Data management, Clinical trials, Clinical research

eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials.

Toronto-based Axiom specializes in electronic data capture (EDC), data management, clinical trial management systems (CTMS), and electronic patient reported outcomes (ePRO) for biotechnology and pharmaceutical sponsors conducting clinical trials.

According to Noah Rhodes, managing director at Great Point Partners, Axiom has been growing at 56% per year over the last six years.

Green Point Partners, which has invested in the clinical trial service industry prior to this recapitalization, approached Axiom regarding the partnership.

While financial details of this recapitalization have not been disclosed, Andrew Schacter, founder and CEO of Axiom said in a statement that, “GPP’s investment will allow Axiom to increase the level of customer service and add additional technology solutions and services.”

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more